Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001044820 | SCV001208639 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2019-03-22 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. A different variant affecting this nucleotide (c.212+3A>G) has been determined to be pathogenic (PMID: 10595255, 15026808, 9150151, 10090482, 12037674, 21673748). This suggests that this nucleotide is important for normal RNA splicing, and that other variants at this position may also be pathogenic. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Experimental studies have shown that this variant disrupts mRNA splicing and/or protein function (PMID: 30209399). This variant has been observed in individuals affected with or at high risk of breast and/or ovarian cancer (PMID: 30702160, 27157322). This variant is not present in population databases (ExAC no frequency). This sequence change falls in intron 4 of the BRCA1 gene. It does not directly change the encoded amino acid sequence of the BRCA1 protein, but it affects a nucleotide within the consensus splice site of the intron. |
Brotman Baty Institute, |
RCV001072652 | SCV001238072 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |